Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease

• Published in: Journal of cerebral blood flow and metabolism Vol. 37; no. 1; pp. 217 - 226
• Main Authors: Lin, Ai-Ling, Jahrling, Jordan B, Zhang, Wei, DeRosa, Nicholas, Bakshi, Vikas, Romero, Peter, Galvan, Veronica, Richardson, Arlan
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2017
• Subjects: Alzheimer Disease - complications; Alzheimer Disease - pathology; Animals; Apolipoprotein E4 - genetics; Blood-Brain Barrier - drug effects; Cerebrovascular Circulation - drug effects; Glucose Metabolism Disorders - drug therapy; Learning Disabilities - drug therapy; Learning Disabilities - prevention & control; Metabolic Diseases - drug therapy; Mice; Mice, Transgenic; Neuroimaging; Original; Secondary Prevention - methods; Secondary Prevention - trends; Sirolimus - pharmacology; Sirolimus - therapeutic use; Vascular Diseases - drug therapy; Brain imaging; blood–brain barrier; cognition; Alzheimer’s disease; cerebral glucose metabolism; inflammation; APOE4; cerebral blood flow; rapamycin

Apolipoprotein E ɛ4 allele is a common susceptibility gene for late-onset Alzheimer's disease. Brain vascular and metabolic deficits can occur in cognitively normal apolipoprotein E ɛ4 carriers decades before the onset of Alzheimer's disease. The goal of this study was to determine whether...